Avoiding Contamination Risks in Aseptic Processes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Avoiding Contamination Risks in Aseptic Processes


Pharmaceutical Technology Europe
Volume 23, Issue 12

Contamination is almost always related to human error and there is a clear drive to reduce human implications in aseptic operations. This can be achieved in multiple ways. Some solutions include:

  • Isolation of the operator: the use of barriers such as isolators and restricted access barrier systems (RABS) are more and more frequently used to separate the filling area from the operator. This trend has been reinforced by the tendency of regulatory authorities to increase their scrutiny on aseptic filling facilities that use old designs, such as clean rooms.
  • Use of disposables: disposables can reduce the cost of operations, including labour work in cleaning, cleaning validation and QA/QC. The cost of disposables is, of course, higher, but the total cost is reduced.
  • Reduction of exposure: exposure is recognised as a contamination risk. Few people claim that the filling environment is guaranteed contamination free. Therefore, several technologies have been developed to help reduce exposure, such as by using specialised containers; for example, many people have reported projects being launched using Blow-Fill-Seal (BFS) containers in recent years. BFS is well known to strongly minimise exposure thanks to the very short cycle times before the container is fully closed.


Benoît Verjans
When it comes to equipment, the main contamination risks are the contact parts, exposure risk and operator intervention, but specialised equipment, particularly barrier systems, can help to minimise all of these. Barrier systems have multiple advantages. Firstly, the operator, is kept away from the filling area by physical separation. The quality of such design has been recognised by authorities and led to significant changes in facility design. For example, isolators are usually located in ISO8 clean room instead of ISO7 clean room with all the savings attached to the simplification of the facility design and the ease of operations.

Operations such as clean-in-place (CIP) and steam-in-place (SIP)—though designed to optimise the sterility assurance level of product contact parts—remain complex and, consequently, are a source of contamination because of potential errors. Compared with these operations, the use of connectors to cross barriers and disposable sterile product paths are simple solutions to set up product path in robust aseptic conditions. In addition, containers may help to minimise contact parts. For example, the insides of ampoules, BFS and Crystal vials are never in contact with equipment contrary to vials and prefilled syringes with their respective stoppers and plungers in contact with vibrating bowls and ramps.

Length of exposure to the environment is also an issue because the probability of contaminants entering the container is higher if the exposure time is longer. On that basis, containers that require very short operating time are preferable to ones requiring longer steps. Three container bodies help minimise exposure to the environment: prefilled syringes, which are supplied sterile in tubs and immediately processed through filling and plunger placement; BFS, which is immediately filled after moulding at high temperature; and the closed vial which is kept permanently closed and immediately processed to filling and laser re-sealing. On the contrary, open classical glass vials and ampoules wait a long time fully open from the hot air tunnel to the filling and closing stations. Unfortunately for prefilled syringes, plungers, as the vial stoppers, are still exposed for long periods of time in vibrating bowls.

Another risk is operator intervention because humans are always a source of contamination. Equipment manufacturers have the task of making systems more reliable and reducing the number of steps. One recent trend in the pharma industry is to reduce the speed of filling equipment in order to minimise short stops. The result is that the output is not so affected thanks to the elimination of many short stops and the quality is improved.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here